Shares of Recursion Pharmaceuticals surged +10.4% to $4.13 as the AI-driven biotech orchestrated a carefully timed trifecta: updated trial data for two key drugs, a Sanofi partnership milestone, and a $200 million stock sale — a mix of good news and shareholder dilution that leaves investors weighing hope against hard math.
A Polyp-Shrinking Drug Inches Toward Approval in a $15 Billion Market
Recursion's lead drug candidate showed a 47% median reduction in precancerous polyp burden after 12 weeks of treatment, with 85% of patients maintaining reductions below baseline even 12 weeks after stopping treatment. The drug targets familial adenomatous polyposis (FAP) — a genetic condition that causes hundreds of precancerous growths in the gut. It has FDA Orphan Drug and Fast Track designations, and targets a market the company estimates at roughly $15 billion, affecting more than 50,000 patients in the U.S. and Europe with zero approved drug therapies. Durable responses off treatment could strengthen the case for a streamlined regulatory path.
Sanofi's $10 Million Check Validates the AI Platform — With $300 Million More on the Table
Sanofi's decision to option a drug candidate from the collaboration triggered a $10 million milestone, bringing total payments to Recursion to $144 million.
Recursion's operational work on this candidate is now complete, meaning all future payments are pure profit.
The company remains eligible for more than $300 million in additional milestones plus double-digit royalties if the drug reaches market. For a company burning nearly $390 million annually, each partnership dollar helps validate the business model.
A $200 Million Stock Sale at a 13% Discount Extends Survival but Dilutes Owners
Recursion priced 61.54 million new shares at $3.25 apiece — a 13% discount to the prior close. Combined with roughly $561 million in existing cash, the proceeds push the company's runway into 2029.
Shares initially fell more than 4% premarket on the dilution news before the clinical data reversed the mood. The offering was oversubscribed, attracting Janus Henderson, ARK Invest, and Invus , signaling institutional conviction — but existing shareholders now own a meaningfully smaller slice of the pie.
Early Cancer Drug Responses Add a Second Shot on Goal
Recursion's second drug showed two confirmed partial responses in endometrial cancer and a 91.7% disease control rate at higher doses , with early data showing encouraging safety signals . A second viable clinical asset reduces the company's single-program risk but remains very early stage.
The stock's rebound says the market is betting clinical momentum outweighs dilution — for now.